Edited by: Bodo Niggemann
Randomized controlled trial of fish oil supplementation in pregnancy on childhood allergies
Article first published online: 21 SEP 2013
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Volume 68, Issue 11, pages 1370–1376, November 2013
How to Cite
Randomized controlled trial of fish oil supplementation in pregnancy on childhood allergies. Allergy 2013; 68: 1370–1376., , , , , , .
- Issue published online: 30 OCT 2013
- Article first published online: 21 SEP 2013
- Manuscript Accepted: 1 JUL 2013
- Australian National Health and Medical Research Council. Grant Number: 399389
- Australian Egg Corporation Limited
- Efamol, UK
- allergy prevention;
- fatty acids;
- randomized controlled trial
Diets high in n-3 long chain polyunsaturated fatty acids (LCPUFA) may modulate the development of IgE-mediated allergic disease and have been proposed as a possible allergy prevention strategy. The aim of this study was to determine whether n-3 LCPUFA supplementation of pregnant women reduces IgE-mediated allergic disease in their children.
Follow-up of children (n = 706) at hereditary risk of allergic disease in the Docosahexaenoic Acid to Optimise Mother Infant Outcome randomized controlled trial. The intervention group (n = 368) was randomly allocated to receive fish oil capsules (providing 900 mg of n-3 LCPUFA daily) from 21 weeks' gestation until birth; the control group (n = 338) received matched vegetable oil capsules without n-3 LCPUFA. The diagnosis of allergic disease was made during medical assessments at 1 and 3 years of age.
No differences were seen in the overall percentage of children with IgE-mediated allergic disease in the first 3 years of life between the n-3 LCPUFA and control groups (64/368 (17.3%) vs 76/338 (22.6%); adjusted relative risk 0.78; 95% CI 0.58–1.06; P = 0.11). Eczema was the most common allergic disease; 13.8% of children in the n-3 LCPUFA group had eczema with sensitization compared with 19.0% in the control group (adjusted relative risk 0.75; 95% CI 0.53–1.05; P = 0.10).
Overall, n-3 LCPUFA supplementation during pregnancy did not significantly reduce IgE-associated allergic disease in the first 3 years of life. Further studies should examine whether the nonsignificant reductions in IgE-associated allergies are of clinical and public health significance.